Everything you need to win Exscientia — in one platform.
Who to reach, what to say, and why now on Exscientia — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Exscientia — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
Oct 16, 2024•over 1 year ago
Contract Type
partnership
BiotechnologyHealth Care
Description
Exscientia has achieved milestones for two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds have met the product profile requirements and have shown a high level of differentiation in early profiling, with the potential to produce best-in-class assets. Exscientia is eligible to receive additional pre-commercial milestone payments of over $300 million and commercial milestones of over $300 million, as well as tiered royalties on product sales.
Company Information
Company
Exscientia
About
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.
